316 related articles for article (PubMed ID: 35831189)
1. [Pathophysiology of hematological malignancies associated with ASXL1 mutations].
Fujino T
Rinsho Ketsueki; 2022; 63(6):561-572. PubMed ID: 35831189
[TBL] [Abstract][Full Text] [Related]
2. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
Asada S; Kitamura T
Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
[TBL] [Abstract][Full Text] [Related]
3. [Role of ASXL1 mutation in myeloid malignancies].
Sheng MY; Zhou Y; Xu MJ; Yang FC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1183-7. PubMed ID: 25130853
[TBL] [Abstract][Full Text] [Related]
4. ASXL1 mutation in clonal hematopoiesis.
Fujino T; Kitamura T
Exp Hematol; 2020 Mar; 83():74-84. PubMed ID: 31945396
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC; Agosto-Peña J
Int J Hematol; 2023 Jun; 117(6):791-806. PubMed ID: 37062051
[TBL] [Abstract][Full Text] [Related]
6. The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia.
D'Altri T; Wilhelmson AS; Schuster MB; Wenzel A; Kalvisa A; Pundhir S; Meldgaard Hansen A; Porse BT
Haematologica; 2021 Apr; 106(4):1000-1007. PubMed ID: 32381577
[TBL] [Abstract][Full Text] [Related]
7. The role of ASXL1 in hematopoiesis and myeloid malignancies.
Asada S; Fujino T; Goyama S; Kitamura T
Cell Mol Life Sci; 2019 Jul; 76(13):2511-2523. PubMed ID: 30927018
[TBL] [Abstract][Full Text] [Related]
8. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
Gelsi-Boyer V; Brecqueville M; Devillier R; Murati A; Mozziconacci MJ; Birnbaum D
J Hematol Oncol; 2012 Mar; 5():12. PubMed ID: 22436456
[TBL] [Abstract][Full Text] [Related]
9. Role of ASXL1 in hematopoiesis and myeloid diseases.
Gao X; You X; Droin N; Banaszak LG; Churpek J; Padron E; Geissler K; Solary E; Patnaik MM; Zhang J
Exp Hematol; 2022 Nov; 115():14-19. PubMed ID: 36183966
[TBL] [Abstract][Full Text] [Related]
10. Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.
Ye B; Sheng Y; Zhang M; Hu Y; Huang H
Cancer Lett; 2022 Jul; 538():215691. PubMed ID: 35469959
[TBL] [Abstract][Full Text] [Related]
11. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
12. How predictive is the finding of clonal hematopoiesis for the development of myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML)?
Steensma DP
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101327. PubMed ID: 34865699
[TBL] [Abstract][Full Text] [Related]
13. [Clonal haematopoiesis: A concise review].
Danlos FX; Papo M; Micol JB
Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
[TBL] [Abstract][Full Text] [Related]
14. Clonal hematopoiesis and preleukemia-Genetics, biology, and clinical implications.
Hartmann L; Metzeler KH
Genes Chromosomes Cancer; 2019 Dec; 58(12):828-838. PubMed ID: 30939217
[TBL] [Abstract][Full Text] [Related]
15. Clonal hematopoiesis in acquired aplastic anemia.
Ogawa S
Blood; 2016 Jul; 128(3):337-47. PubMed ID: 27121470
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
Zhang A; Wang S; Ren Q; Wang Y; Jiang Z
Asia Pac J Clin Oncol; 2023 Oct; 19(5):e183-e194. PubMed ID: 36471477
[TBL] [Abstract][Full Text] [Related]
17. Clonal Hematopoiesis and risk of Acute Myeloid Leukemia.
Desai P; Hassane D; Roboz GJ
Best Pract Res Clin Haematol; 2019 Jun; 32(2):177-185. PubMed ID: 31203999
[TBL] [Abstract][Full Text] [Related]
18. Truncation mutants of ASXL1 observed in myeloid malignancies are expressed at detectable protein levels.
Inoue D; Matsumoto M; Nagase R; Saika M; Fujino T; Nakayama KI; Kitamura T
Exp Hematol; 2016 Mar; 44(3):172-6.e1. PubMed ID: 26700326
[TBL] [Abstract][Full Text] [Related]
19. Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.
Stengel A; Baer C; Walter W; Meggendorfer M; Kern W; Haferlach T; Haferlach C
Blood Adv; 2021 Nov; 5(21):4426-4434. PubMed ID: 34570179
[TBL] [Abstract][Full Text] [Related]
20. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
